Navigation Links
Genova files patent for new prostate cancer treatment
Date:9/8/2009

e implications are tremendous." Licensing to companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec could prove to be extremely lucrative in the short and long term. GENova works very hard on a daily basis to close agreements with big Biotechnology players in the industry.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies. Visit GENova online at www.genovabio.comForward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.


'/>"/>
SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. GENova names Dr. John Savin as Vice President
2. GENova names Aaron Whiteman as CEO
3. Sun Pharmaceutical Files HSR Application for Taro Tender Offer
4. InfoLogix Files Preliminary Proxy Statement in Connection with Special Meeting of Its Stockholders to Approve Recapitalization Plan
5. VirtualHealth Technologies Files 8k Related to the August 17th Announcement of Private Access Payment and Document Modification
6. Profiles International Releases New Study Identifying Key Factors for Strategic Workforce Planning
7. "Med Records to Go" Stores Document and Image Files of Medical Facilities for Emergency Viewing
8. AMDL Inc. Files Notification of Late Filing for Form 10-Q
9. Texas Law Firm Files Multiple Suits Against Medtronic as Deadline Approaches
10. Star Scientific Files Second Quarter Financial Results; Rock Creek Pharmaceuticals Reports Early Promising Results in Studies Assessing Safety and Viability of Active Components for a Non-Nicotine Nutraceutical (CigRx(TM))
11. Vitamin Shoppe Files Registration Statement for Initial Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Blood Thinner Combos Risky for Heart Attack Patients 2Health News:Centegra Expands H1N1 Vaccines to General Public 2Health News:Centegra Expands H1N1 Vaccines to General Public 3Health News:Centegra Expands H1N1 Vaccines to General Public 4Health News:Do Charitable Gift Donations Make a Difference? 2Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 2Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 3Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 4Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 5Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 6Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 7Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 8Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 9Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 10Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 11Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 12Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 13Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 14Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 15Health News:China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009 16Health News:Hard to Treat Diseases (HTDS) Comments on Recent Movement Of Its Security 2Health News:Hard to Treat Diseases (HTDS) Comments on Recent Movement Of Its Security 3Health News:Hard to Treat Diseases (HTDS) Comments on Recent Movement Of Its Security 4Health News:Hard to Treat Diseases (HTDS) Comments on Recent Movement Of Its Security 5Health News:Hard to Treat Diseases (HTDS) Comments on Recent Movement Of Its Security 6
Other Medicine News:Health News:Most Kidney Donors Lead Long, Healthy Lives 2Health News:Most Kidney Donors Lead Long, Healthy Lives 3Health News:NBTY Reports First Quarter Results 2Health News:NBTY Reports First Quarter Results 3Health News:NBTY Reports First Quarter Results 4Health News:NBTY Reports First Quarter Results 5Health News:NBTY Reports First Quarter Results 6Health News:NBTY Reports First Quarter Results 7Health News:NBTY Reports First Quarter Results 8Health News:NBTY Reports First Quarter Results 9Health News:NBTY Reports First Quarter Results 10Health News:NBTY Reports First Quarter Results 11Health News:NBTY Reports First Quarter Results 12Health News:NBTY Reports First Quarter Results 13Health News:NBTY Reports First Quarter Results 14Health News:NBTY Reports First Quarter Results 15Health News:NBTY Reports First Quarter Results 16Health News:Medical College of Wisconsin recognized for AIDS intervention research 2Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 2Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 3Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 4Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 5Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 6Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 7Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 8Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 9Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 10Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 11Health News:Covance Reports Fourth Quarter and Full-Year 2008 Results 12Health News:Toxic Causation Training Day for Attorneys 2
Breaking Medicine Technology:Within3 Expands into Mobile Applications 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2RecoverCare and MedaSTAT USA Complete Transaction 53601 1RecoverCare and MedaSTAT USA Complete Transaction 53601 2RecoverCare and MedaSTAT USA Complete Transaction 53601 3BMP Sunstone Divests Ownership Stake in Alliance BMP Limited 53599 1BMP Sunstone Divests Ownership Stake in Alliance BMP Limited 53599 2AlphaRx and Venturepharm Announce Collaboration Agreement 53597 1AlphaRx and Venturepharm Announce Collaboration Agreement 53597 2